OBJECTIVES From the total healthcare costs in Slovak Republic the costs of medicines for treatment of cardiovascular diseases represent about 25%. In the world the proportion is at 8-10%. Accurate data on morbidity from cardiovascular disease in Slovak Republic is not available. National Health Information Center is processing the data on prevalence and incidence of circulatory system diseases, but this includes only those patients who are followed in cardiology in SR. Reportedly, the prevalence of cardiovascular diseases in SR is about 250 000 patients (50.8/ 1000 inhabitants). METHODS The utilization of medicines in period from 2008 to 2013 for treatment of cardiovascular diseases was analysed quantitatively by inderect descriptiv method of evaluating supply of medicines in quantitative units (number of packages), in the number of DDD and in financial indicators reflecting the full value of consumed package. Data were gained from National Health Center and State Institute of Drug Control RESULTS The decline of consumption expressed in number of packages was observed in the group of cardiac therapy and by peripheral vasodilatators. The groups of beta blocking agents, agents acting on the renin-angiotensin system and lipid modifying agents showed increase in consumption.  In DDD units the consumption deacreased most significantly in the group of peripheral vasodilatators. Rise in DDD units was observed in the group of beta blocking agents, antihypertesives, beta blocking agents, agents acting on the renin-angiotensin system and lipid modifying agents. Atorvastatin was active agent with highest consumption in DDD. The highest average price per package was calculated by lipid modifying agents. After access of generic drugs to the market in 2008 the consumption in financial units declined while consumption in DDD grew in followed period. CONCLUSIONS By using the same amount of healthcare expenditures there is the possibility to provide treatment to more patients with cardiovascular disease.